Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.
Risk and Volatility
Dianthus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Institutional & Insider Ownership
47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Dianthus Therapeutics and Cardiff Oncology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $2.04 million | 2,231.11 | -$162.34 million | ($4.15) | -20.01 |
| Cardiff Oncology | $590,000.00 | 115.23 | -$45.85 million | ($0.60) | -1.46 |
Cardiff Oncology has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Dianthus Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Dianthus Therapeutics and Cardiff Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
Dianthus Therapeutics currently has a consensus price target of $128.54, suggesting a potential upside of 54.76%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 758.12%. Given Cardiff Oncology’s higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Dianthus Therapeutics.
Summary
Dianthus Therapeutics beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
